Related Experiment Video
Updated: Jul 4, 2025
13:00
Engineering Antiviral Agents via Surface Plasmon Resonance
Published on: June 14, 2022
2.3K
BRD4354 Is a Potent Covalent Inhibitor against the SARS-CoV-2 Main Protease
Yan J Sheng1, Syuan-Ting A Kuo1, Tingyuan Yang1
1Department of Chemistry, Texas A&M University, College Station, Texas 77843, United States.
Biochemistry
|February 8, 2024
Summary
BRD4354 is a potent inhibitor of SARS-CoV-2 main protease (MPro). This organic molecule forms a covalent bond with the enzyme, suggesting its potential for developing new COVID-19 therapeutics.
Area of Science:
- Biochemistry
- Medicinal Chemistry
- Virology
Background:
- SARS-CoV-2 main protease (MPro) is a key target for COVID-19 drug development.
- Previous research explored zinc-ligand inhibitors for MPro and HDACs.
- Organic molecules offer potential for inhibiting viral proteases.
Purpose of the Study:
- To identify and characterize novel inhibitors of SARS-CoV-2 MPro.
- To investigate the mechanism of inhibition by BRD4354.
- To evaluate BRD4354 as a potential anti-COVID therapeutic.
Main Methods:
- In vitro protease activity assays to determine IC50 and kinetic parameters.
- Native mass spectrometry to identify covalent interactions.
- Proposed a Michael-addition reaction mechanism.
Main Results:
- BRD4354 demonstrated time-dependent inhibition of MPro with an IC50 of 0.72 ± 0.04 μM.
- A two-step inactivation process was observed, involving rapid binding and slow inactivation.
- Native mass spectrometry confirmed a covalent bond formation between BRD4354 and MPro's catalytic cysteine C145.
- A Michael-addition mechanism was proposed for the inhibition.
Conclusions:
- BRD4354 is a potent covalent inhibitor of SARS-CoV-2 MPro.
- The identified mechanism provides insight into drug-target interactions.
- Further preclinical testing and SAR studies of BRD4354 are warranted for anti-COVID drug development.
More Related Videos
Related Concept Videos
01:30Enzyme Inhibition
78.3K
Inhibitors are molecules that reduce enzyme activity by binding to the enzyme. In a normally functioning cell, enzymes are regulated by a variety of inhibitors. Drugs and other toxins can also inhibit enzymes. Some inhibitors bind to the enzyme’s active site, while others inhibit enzymatic activity by binding to other sites on the protein structure.
78.3K
02:47Ribozymes
12.3K
The term ribozyme is used for RNA that can act as an enzyme. Ribozymes are mainly found in selected viruses, bacteria, plant organelles, and lower eukaryotes. Ribozymes were first discovered in 1982 when Tom Cech’s laboratory observed Group I introns acting as enzymes. This was shortly followed by the discovery of another ribozyme, Ribonulcease P, by Sid Altman’s laboratory. Both Cech and Altman received the Nobel Prize in chemistry in 1989 for their work on ribozymes.
Ribozymes can...
Ribozymes can...
12.3K
01:16Protein-Drug Binding: Mechanism and Kinetics
477
Protein-drug binding refers to the interaction between drugs and proteins within the body. This binding process can occur intracellularly, involving drug interactions with enzymes or receptors within cells, or extracellularly, involving plasma proteins in the blood.
Various forces drive these interactions, including hydrogen bonds, hydrophobic interactions, ionic bonds, electrostatic interactions, and van der Waals forces. These bonds enable drugs to bind to specific sites on proteins,...
Various forces drive these interactions, including hydrogen bonds, hydrophobic interactions, ionic bonds, electrostatic interactions, and van der Waals forces. These bonds enable drugs to bind to specific sites on proteins,...
477
01:23RNA Interference
26.0K
RNA interference (RNAi) is a process in which a small non-coding RNA molecule blocks the post-transcriptional expression of a gene by binding to its messenger RNA (mRNA) and preventing the protein from being translated.
This process occurs naturally in cells, often through the activity of genomically-encoded microRNAs. Researchers can take advantage of this mechanism by introducing synthetic RNAs to deactivate specific genes for research or therapeutic purposes. For example, RNAi could be used...
This process occurs naturally in cells, often through the activity of genomically-encoded microRNAs. Researchers can take advantage of this mechanism by introducing synthetic RNAs to deactivate specific genes for research or therapeutic purposes. For example, RNAi could be used...
26.0K
02:34Inhibition of Cdk Activity
4.8K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.8K
01:13Induced-fit Model
80.8K
Most chemical reactions in cells require enzymes—biological catalysts that speed up the reaction without being consumed or permanently changed. They reduce the activation energy needed to convert the reactants into products. Enzymes are proteins, that usually work by binding to a substrate—a reactant molecule that they act upon.
Enzymes exhibit substrate specificity, meaning that they can only bind to certain substrates. This is mainly determined by the shape and chemical...
Enzymes exhibit substrate specificity, meaning that they can only bind to certain substrates. This is mainly determined by the shape and chemical...
80.8K